Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction

ABSTRACT Bacteroides fragilis group (BFG) are the most frequently recovered anaerobic bacteria from human infections, and resistance to frontline antibiotics is emerging. In the absence of routine antimicrobial susceptibility testing (AST) for BFG in most clinical settings, we assessed the utility o...

Full description

Bibliographic Details
Main Authors: Miranda J. Wallace, Sophonie Jean, Meghan A. Wallace, Carey-Ann D. Burnham, Gautam Dantas
Format: Article
Language:English
Published: American Society for Microbiology 2022-02-01
Series:mBio
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/mbio.03603-21
_version_ 1819279471722627072
author Miranda J. Wallace
Sophonie Jean
Meghan A. Wallace
Carey-Ann D. Burnham
Gautam Dantas
author_facet Miranda J. Wallace
Sophonie Jean
Meghan A. Wallace
Carey-Ann D. Burnham
Gautam Dantas
author_sort Miranda J. Wallace
collection DOAJ
description ABSTRACT Bacteroides fragilis group (BFG) are the most frequently recovered anaerobic bacteria from human infections, and resistance to frontline antibiotics is emerging. In the absence of routine antimicrobial susceptibility testing (AST) for BFG in most clinical settings, we assessed the utility of clinical and modern genomics tools to determine BFG species-level identification and resistance patterns. A total of 174 BFG clinical isolates supplemented with 20 archived carbapenem-resistant B. fragilis sensu stricto (BFSS) isolates underwent antimicrobial susceptibility testing, MALDI-ToF mass-spectrometry, and whole-genome sequencing (WGS). Bruker BioTyper and VITEK-MS MALDI-ToF systems demonstrated accurate species-level identifications (91% and 90% agreement, respectively) compared to average nucleotide identity (ANI) analysis of WGS data. Distinct β-lactamase gene profiles were observed between BFSS and non-fragilis Bacteroides species, with significantly higher MICs to piperacillin-tazobactam in B. vulgatus and B. thetaiotaomicron relative to BFSS (P ≤ 0.034). We also uncovered phylogenetic diversity at the genomospecies level between division I and division II BFSS (ANI <0.95) and demonstrate that division II BFSS strains harbor an increased capacity to achieve carbapenem resistance through chromosomal activation of the CfiA carbapenemase. Finally, we report that CfiA detection by the Bruker BioTyper Subtyping Module accurately detected carbapenem resistance in BFSS with positive and negative percent agreement of 94%/90% and 95%/95% compared to ertapenem and meropenem susceptibility, respectively. These comparative analyses indicate that resistance mechanisms are distinct at both the phenotypic and genomic level across species within the BFG and that modern MALDI-ToF identification systems can be used for accurate species-level identification and resistance prediction of the BFG. IMPORTANCE Anaerobic infections present unique challenges in terms of detecting and identifying the etiologic agent and selecting the optimal antimicrobial therapy. Antimicrobial resistance is increasing in anaerobic pathogens, and it is critical to understand the prevalence and mechanisms of resistance to commonly prescribed antimicrobial therapies. This study uses comparative genomics to validate clinical tools for species-level identification and phenotypic resistance prediction in 194 isolates of Bacteroides fragilis group (BFG) bacteria, which represent the most commonly isolated organisms among anaerobic infections. We demonstrate species-specific patterns in antimicrobial resistance and validate new strategies for species-level organism identification and phenotypic resistance prediction in a routine clinical laboratory setting. These findings expand our understanding and management of anaerobic infections and justify further investigations into the molecular basis for species-specific resistance patterns observed within this study.
first_indexed 2024-12-24T00:28:26Z
format Article
id doaj.art-9be79e0ed77548e5bfff602cfecd8f92
institution Directory Open Access Journal
issn 2150-7511
language English
last_indexed 2024-12-24T00:28:26Z
publishDate 2022-02-01
publisher American Society for Microbiology
record_format Article
series mBio
spelling doaj.art-9be79e0ed77548e5bfff602cfecd8f922022-12-21T17:24:21ZengAmerican Society for MicrobiologymBio2150-75112022-02-0113110.1128/mbio.03603-21Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance PredictionMiranda J. Wallace0Sophonie Jean1Meghan A. Wallace2Carey-Ann D. Burnham3Gautam Dantas4Department of Pathology &amp; Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USADepartment of Pathology and Laboratory Medicine, Nationwide Children’s Hospital, The Ohio State University Wexner Medical Center, Columbus, OH, USADepartment of Pathology &amp; Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USADepartment of Pathology &amp; Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USADepartment of Pathology &amp; Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, MO, USAABSTRACT Bacteroides fragilis group (BFG) are the most frequently recovered anaerobic bacteria from human infections, and resistance to frontline antibiotics is emerging. In the absence of routine antimicrobial susceptibility testing (AST) for BFG in most clinical settings, we assessed the utility of clinical and modern genomics tools to determine BFG species-level identification and resistance patterns. A total of 174 BFG clinical isolates supplemented with 20 archived carbapenem-resistant B. fragilis sensu stricto (BFSS) isolates underwent antimicrobial susceptibility testing, MALDI-ToF mass-spectrometry, and whole-genome sequencing (WGS). Bruker BioTyper and VITEK-MS MALDI-ToF systems demonstrated accurate species-level identifications (91% and 90% agreement, respectively) compared to average nucleotide identity (ANI) analysis of WGS data. Distinct β-lactamase gene profiles were observed between BFSS and non-fragilis Bacteroides species, with significantly higher MICs to piperacillin-tazobactam in B. vulgatus and B. thetaiotaomicron relative to BFSS (P ≤ 0.034). We also uncovered phylogenetic diversity at the genomospecies level between division I and division II BFSS (ANI <0.95) and demonstrate that division II BFSS strains harbor an increased capacity to achieve carbapenem resistance through chromosomal activation of the CfiA carbapenemase. Finally, we report that CfiA detection by the Bruker BioTyper Subtyping Module accurately detected carbapenem resistance in BFSS with positive and negative percent agreement of 94%/90% and 95%/95% compared to ertapenem and meropenem susceptibility, respectively. These comparative analyses indicate that resistance mechanisms are distinct at both the phenotypic and genomic level across species within the BFG and that modern MALDI-ToF identification systems can be used for accurate species-level identification and resistance prediction of the BFG. IMPORTANCE Anaerobic infections present unique challenges in terms of detecting and identifying the etiologic agent and selecting the optimal antimicrobial therapy. Antimicrobial resistance is increasing in anaerobic pathogens, and it is critical to understand the prevalence and mechanisms of resistance to commonly prescribed antimicrobial therapies. This study uses comparative genomics to validate clinical tools for species-level identification and phenotypic resistance prediction in 194 isolates of Bacteroides fragilis group (BFG) bacteria, which represent the most commonly isolated organisms among anaerobic infections. We demonstrate species-specific patterns in antimicrobial resistance and validate new strategies for species-level organism identification and phenotypic resistance prediction in a routine clinical laboratory setting. These findings expand our understanding and management of anaerobic infections and justify further investigations into the molecular basis for species-specific resistance patterns observed within this study.https://journals.asm.org/doi/10.1128/mbio.03603-21Bacteroidesanaerobesantibiotic resistancebeta-lactamscarbapenemsgenomics
spellingShingle Miranda J. Wallace
Sophonie Jean
Meghan A. Wallace
Carey-Ann D. Burnham
Gautam Dantas
Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction
mBio
Bacteroides
anaerobes
antibiotic resistance
beta-lactams
carbapenems
genomics
title Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction
title_full Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction
title_fullStr Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction
title_full_unstemmed Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction
title_short Comparative Genomics of Bacteroides fragilis Group Isolates Reveals Species-Dependent Resistance Mechanisms and Validates Clinical Tools for Resistance Prediction
title_sort comparative genomics of bacteroides fragilis group isolates reveals species dependent resistance mechanisms and validates clinical tools for resistance prediction
topic Bacteroides
anaerobes
antibiotic resistance
beta-lactams
carbapenems
genomics
url https://journals.asm.org/doi/10.1128/mbio.03603-21
work_keys_str_mv AT mirandajwallace comparativegenomicsofbacteroidesfragilisgroupisolatesrevealsspeciesdependentresistancemechanismsandvalidatesclinicaltoolsforresistanceprediction
AT sophoniejean comparativegenomicsofbacteroidesfragilisgroupisolatesrevealsspeciesdependentresistancemechanismsandvalidatesclinicaltoolsforresistanceprediction
AT meghanawallace comparativegenomicsofbacteroidesfragilisgroupisolatesrevealsspeciesdependentresistancemechanismsandvalidatesclinicaltoolsforresistanceprediction
AT careyanndburnham comparativegenomicsofbacteroidesfragilisgroupisolatesrevealsspeciesdependentresistancemechanismsandvalidatesclinicaltoolsforresistanceprediction
AT gautamdantas comparativegenomicsofbacteroidesfragilisgroupisolatesrevealsspeciesdependentresistancemechanismsandvalidatesclinicaltoolsforresistanceprediction